Wall Street Zen Upgrades SiBone (NASDAQ:SIBN) to Buy

SiBone (NASDAQ:SIBN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also commented on SIBN. Citigroup reissued a “market outperform” rating on shares of SiBone in a research note on Tuesday, November 3rd. Truist Financial lifted their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. UBS Group increased their price target on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Finally, Needham & Company LLC dropped their target price on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

SiBone Price Performance

Shares of SIBN stock opened at $24.24 on Friday. The company has a 50 day simple moving average of $19.81 and a two-hundred day simple moving average of $16.59. The stock has a market cap of $1.09 billion, a P/E ratio of -78.19 and a beta of 0.64. SiBone has a 12 month low of $11.48 and a 12 month high of $25.92. The company has a current ratio of 7.58, a quick ratio of 6.15 and a debt-to-equity ratio of 0.19.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. On average, research analysts expect that SiBone will post -0.34 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Laura Francis sold 75,000 shares of SiBone stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $25.30, for a total transaction of $1,897,500.00. Following the completion of the transaction, the chief executive officer directly owned 304,256 shares of the company’s stock, valued at $7,697,676.80. The trade was a 19.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Dunn sold 20,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $18.47, for a total transaction of $369,400.00. Following the sale, the director owned 16,057 shares in the company, valued at approximately $296,572.79. This represents a 55.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 372,859 shares of company stock worth $8,034,168. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On SiBone

Hedge funds have recently modified their holdings of the company. Diversified Trust Co boosted its stake in shares of SiBone by 26.0% in the third quarter. Diversified Trust Co now owns 34,775 shares of the company’s stock worth $654,000 after acquiring an additional 7,165 shares during the last quarter. D.A. Davidson & CO. increased its position in shares of SiBone by 2.8% during the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock worth $711,000 after purchasing an additional 1,038 shares in the last quarter. First Light Asset Management LLC raised its stake in SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Squarepoint Ops LLC raised its stake in SiBone by 40.3% in the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock valued at $1,928,000 after purchasing an additional 33,947 shares during the last quarter. Finally, VELA Investment Management LLC lifted its holdings in SiBone by 7.4% in the 2nd quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock valued at $3,282,000 after purchasing an additional 13,934 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.